MacroGenics | MGNX - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 6.57B 2.82B 2026-06
Amgen USD 13.99B 1.95B 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
Biogen USD 1.28B 2.1B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Daiichi Sankyo JPY 449.81B 92.35B 2026-03
Eli Lilly USD 8.95B 3.67B 2026-06
Genmab DKK 1.5B 18M 2026-06
Geron USD 62.64M 6.25M 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
J&J USD 20.42B 1.27B 2026-06
Karyopharm Therapeutics USD 90.85M 30.31M 2026-03
MacroGenics USD 113.91M 47.39M 2026-06
Merck USD 6.85B 1.52B 2026-06
Pfizer USD 976M 727M 2026-06
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Xencor USD 44.66M 30.49M 2026-06